These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33589100)

  • 1. Managing Cardiovascular Risk in Patients with Rheumatic Disease.
    Ferguson LD; Sattar N; McInnes IB
    Med Clin North Am; 2021 Mar; 105(2):247-262. PubMed ID: 33589100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing Cardiovascular Risk in Patients with Rheumatic Disease.
    Ferguson LD; Sattar N; McInnes IB
    Rheum Dis Clin North Am; 2022 May; 48(2):429-444. PubMed ID: 35400369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular co-morbidity in rheumatic diseases.
    Turesson C; Jacobsson LT; Matteson EL
    Vasc Health Risk Manag; 2008; 4(3):605-14. PubMed ID: 18827910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Consequences of Autoimmune Rheumatic Diseases.
    Atzeni F; Nucera V; Gerratana E; Fiorenza A; Gianturco L; Corda M; Sarzi-Puttini P
    Curr Vasc Pharmacol; 2020; 18(6):566-579. PubMed ID: 31985379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases.
    Manolis AS; Tzioufas AG
    Curr Vasc Pharmacol; 2020; 18(6):533-537. PubMed ID: 32693768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
    Manolis AS; Tzioufas AG
    Curr Vasc Pharmacol; 2020; 18(5):425-430. PubMed ID: 32410564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).
    Mourouzis IS; Manolis AS; Pantos C
    Curr Vasc Pharmacol; 2020; 18(5):455-462. PubMed ID: 31566134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular co-morbidity in patients with rheumatic diseases.
    Frostegård J
    Arthritis Res Ther; 2011 Jun; 13(3):225. PubMed ID: 21722331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis.
    Leonard D; Svenungsson E; Dahlqvist J; Alexsson A; Ärlestig L; Taylor KE; Sandling JK; Bengtsson C; Frodlund M; Jönsen A; Eketjäll S; Jensen-Urstad K; Gunnarsson I; Sjöwall C; Bengtsson AA; Eloranta ML; Syvänen AC; Rantapää-Dahlqvist S; Criswell LA; Rönnblom L
    Ann Rheum Dis; 2018 Jul; 77(7):1063-1069. PubMed ID: 29514802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speckle tracking echocardiography as a new diagnostic tool for an assessment of cardiovascular disease in rheumatic patients.
    Lo Gullo A; Rodríguez-Carrio J; Gallizzi R; Imbalzano E; Squadrito G; Mandraffino G
    Prog Cardiovasc Dis; 2020; 63(3):327-340. PubMed ID: 32201285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk factors, fitness and physical activity in rheumatic diseases.
    Turesson C; Matteson EL
    Curr Opin Rheumatol; 2007 Mar; 19(2):190-6. PubMed ID: 17278937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular risk in patients with rheumatic disease and its management].
    Laštůvka J; Oreská S; Tomčík M; Vrablík M
    Vnitr Lek; 2018; 64(1):51-59. PubMed ID: 29498876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
    van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
    Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives.
    Mavrogeni SI; Sfikakis PP; Dimitroulas T; Koutsogeorgopoulou L; Katsifis G; Markousis-Mavrogenis G; Kolovou G; Kitas GD
    Rheumatol Int; 2018 Jun; 38(6):949-958. PubMed ID: 29516170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention.
    Kostopoulou M; Nikolopoulos D; Parodis I; Bertsias G
    Curr Vasc Pharmacol; 2020; 18(6):549-565. PubMed ID: 31880245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.
    Tektonidou MG; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Protogerou A
    Autoimmun Rev; 2017 Mar; 16(3):308-312. PubMed ID: 28147263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in autoimmune rheumatic diseases.
    Hollan I; Meroni PL; Ahearn JM; Cohen Tervaert JW; Curran S; Goodyear CS; Hestad KA; Kahaleh B; Riggio M; Shields K; Wasko MC
    Autoimmun Rev; 2013 Aug; 12(10):1004-15. PubMed ID: 23541482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CVD risk in chronic connective tissue disease.
    Malaviya AP; Hall FC
    Practitioner; 2012 Jan; 256(1747):21-6, 3. PubMed ID: 22720456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular comorbidity in rheumatic and musculoskeletal diseases: Where we are and how can we move forward?
    Kitas GD; Dimitroulas T
    Int J Rheum Dis; 2021 Apr; 24(4):473-476. PubMed ID: 33817989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.